Navigation Links
Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía
Date:9/2/2014

entó del 60,6 al 67,5 % en el mismo período, ya que pocos pacientes recibieron un VKA (57,5 a 41,1 %).

Los 12.448 pacientes prospectivos con al menos un año de datos de seguimiento tras el diagnóstico de AF en el momento del análisis se incluyeron en tres pósters presentados en el ESC Congress 2014.

Sólo el 25 % de los pacientes tratados con VKAs logran un adecuado control anticoagulación[3]  

  • Las directrices del ESC sugieren que los pacientes se pueden considerar bien tratados en la terapia VKA si invierten al menos el 70% de su tiempo en el abanico terapéutico, por ejemplo, con una media internacional normalizada (INR) de 2,0-3,0[4].
  • El requisito para los pacientes con VKA de someterse a un control de rutina y ajuste de dosis, además de la dificultad para mantener el efecto anticoagulante óptimo, son de una consideración importante cuando se elige entre terapias anticoagulantes. Las NOACs se dan en dosis fijas y ejercen un efecto anticoagulante predecible sin necesidad de control.
  • De los 5.107 pacientes de GARFIELD-AF tratados con VKAs y con registros INR disponibles, solo el 25% (n=1.301) cumplen con el estándar del 70% para el control VKA (con el control INR evaluado como frecuencia en la gama (FIR)).
  • Los pacientes cuyo control VKA fue sub-óptimo fueron mucho más propensos a padecer apoplejía, un evento hemorrágico importante, y fallecimiento.

2 de cada 5 pacientes de bajo riesgo reciben anticoagulación frente a las recomendaciones de las directrices[5]  

  • Los pacientes que padecen AF y con una puntuación de riesgo CHA2DS2-VASc[6] de 0 se consideran por las directrices ESC co
    '/>"/>

SOURCE GARFIELD-AF
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Adamas Pharmaceuticals presenta datos clínicos positivos para ADS-5102, un tratamiento para la disquinesia inducida por levodopa, en el Congreso Mundial del Parkinson
2. Enciclopedia online gratuita sobre el cáncer para la diagnosis y tratamiento del cáncer
3. Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke
4. One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines
5. EpiCast Report: Atrial Fibrillation - Epidemiology Forecast to 2023
6. Kalila Medical Announces CE Mark Approval For The Vado Steerable Sheath Used During Atrial Fibrillation Procedures
7. Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
8. Global Atrial Fibrillation Market Report 2013 - 2019
9. The Novel Oral Anticoagulants Will Continue to Drive Growth in the Atrial Fibrillation Drug Market
10. Daiichi Sankyos Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
11. Phase IIb Study of Vanoxerine Shows Strong Safety and Statistically Significant Efficacy Signals for Treatment of Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... HOUSTON , Dec. 22, 2014 Cyberonics, Inc. ... devices for the treatment and management of epilepsy, today announced ... Morgan Healthcare Conference on Wednesday, January 14, 2015, in ... , Cyberonics, President and Chief Executive Officer, will speak at ... presentation can be accessed by clicking on the Investor Relations ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... issued the following open letter to shareholders from ... Med. Sc. Dear RXi Shareholders, ... of inaccurate statements posted on certain social media ...
(Date:12/22/2014)... ALTO, Calif. , Dec, 22, 2014 /PRNewswire/ ... a Phase 2a study of lonafarnib in patients ... study was conducted at the National Institutes of ... Maryland .  The double-blinded, randomized, placebo-controlled, dose ... mg twice daily and 200 mg twice daily ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... the University of Illinois at Chicago are taking part ... 2,000 autism patients and their families over the next ... Collection, is the first coordinated effort to create a ... child. , "This collection of DNA will allow researchers ...
... since last year mean seniors should shop wisely, experts ... the enrollment period for Medicare,s Part D prescription drug ... are advising seniors to choose a plan carefully because ... plan. , "As we enter the fourth year of ...
... published by The Feinstein Institute for Medical ... and disease pathogenesis at the molecular level ... use that knowledge in the design of ... prognosis, and prevention. Featured in the ...
... software free of charge to customers purchasing its market leading ... ... Fort Collins, CO (PRWEB) November 14, 2008 -- Privacy ... Email Integrity Program for customers purchasing Privacy Networks, market leading ...
... diagnostic measures, British researchers report , , THURSDAY, Nov. 13 ... standard test for measuring the activity of the heart ... problems for people who are examined because of chest ... stable chest pain, suspected angina, the resting EKG was ...
... Nov. 13 The U.S. government,through the U.S. ... five planned shipments of U.S. emergency assistance to ... In coordination with the,UN Children,s Fund (UNICEF), approximately ... 5,400 water containers, 500,rolls of plastic sheeting, and ...
Cached Medicine News:Health News:UIC joins international research effort to study autism 2Health News:Enrollment for Medicare Drug Plans Begins Again 2Health News:Enrollment for Medicare Drug Plans Begins Again 3Health News:Researchers Tackle CLL, Diabetes and Trauma-Hemorrhage, 2Health News:Message Archiving Leader Privacy Networks Announces Free Anti-Spam Software to Businesses and Organizations 2Health News:Message Archiving Leader Privacy Networks Announces Free Anti-Spam Software to Businesses and Organizations 3Health News:EKG Not Strong Predictor of Heart Risk 2Health News:EKG Not Strong Predictor of Heart Risk 3Health News:First U.S. Flight with Humanitarian Goods Arrives in Democratic Republic of Congo 2
REFRESH TEARS® lubricating eye drops does more than just smoothe and relieve dry, irritated eyes. REFRESH TEARS® creates a shield of protection against further irritation with its unique, lon...
... REFRESH ENDURA™ is the ... to benefit all 3 layers ... coating of moisture that lubricates ... your eyes). This helps seal ...
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
... solution is a prescription eye drop ... to use after your cataract surgery. ... may cause them to become inflamed. ... inflammation include redness and swelling. If ...
Medicine Products: